Tumor Vaccine Based on Targeted Neoantigen: A Powerful Immunotherapy Weapon in Acute Meyroid Leukemia
Keywords:
Tumor Vaccine, Neoantigen, Immunotherapy, Acute Meyroid Leukemia
Abstract
Acute myeloid leukemia (AML) is a common type of leukemia. The existing chemotherapy regimens and hematopoietic stem cell transplantation can not achieve the ideal treatment effect, and more efficient treatment methods are needed in the clinical treatment of AML patients. As a star method of immunotherapy, tumor vaccines have attracted much attention. Choosing neoantigen as the target antigen in vaccine is a new and exploreable design plan for AML. In this review, we will carefully summarize the current neoantigen-related vaccine research progress, reasonably speculate its application prospects in AML, and put forward the key challenges and risks in the research.
References
[1] Burd, A., Levine, R.L., Ruppert, A. S., et al. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial.[J] .Nat Med, 2020, 26: 1852-1858.
[2] Tefferi, A,Vardiman, J.W., Myelodysplastic syndromes. [J] .N Engl J Med, 2009, 361: 1872-85.
[3] Tallman, M.S.,Wang, E.S., Altman, J.K., et al. Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.[J] .J Natl Compr Canc Netw, 2019, 17: 721-749.
[4] Elsayad, K., Oertel, M., Haverkamp, U., et al. The effectiveness of radiotherapy for leukemia cutis.[J] .J Cancer Res Clin Oncol, 2017, 143: 851-859.
[5] Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association,[Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2017)].[J] . Zhonghua Xue Ye Xue Za Zhi, 2017, 38: 177-182.
[6] Chevallier P., Mohty, M., Lioure, B., et al. Allogeneic hematopoietic stem-cell transplantation for myeloid sarcoma: a retrospective study from the SFGM-TC. [J] .J Clin Oncol, 2008, 26: 4940-3.
[7]Creutzig, U.,van den Heuvel-Eibrink Marry M,Gibson, B. et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel.[J] .Blood, 2012, 120: 3187-205.
[8] Saxena, M., van der Burg Sjoerd H, Melief, C. J. M., et al. Therapeutic cancer vaccines.[J] .Nat Rev Cancer, 2021, 21: 360-378.
[9] Arribillaga L., Echeverria, I., Belsue, V., et al. Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens.[J] . J Immunother Cancer, 2020, 8: undefined.
[10] Kim, C.G., Sang, Y.b., Lee, J.H., et al. Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach.[J] .Int J Mol Sci, 2021, 22: undefined.
[11] Cheever, M.A., Higano, C. S., PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.[J] .Clin Cancer Res, 2011, 17: 3520-6.
[12] Rocconi, R.P., Grosen, E.A, Ghamande, S.A., et al. Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.[J] .Lancet Oncol, 2020, 21: 1661-1672.
[13] Kalli, K.R., Block, M.S., Kasi, P. M., et al. Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients.[J] .Clin Cancer Res, 2018, 24: 3014-3025.
[14] Dammeijer, F., Lievense, L.A.,Veerman, G.D., Marijn et al. Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.[J] .J Clin Oncol, 2016, 34: 3204-12.
[15] Ott, P.A., Hu-Lieskovan, S.W.,Chmielowski, B., et al. A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.[J] .Cell, 2020, 183: 347-362.e24.
[16] Sahin, U., Oehm, P., Derhovanessian, E., et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma.[J] .Nature, 2020, 585: 107-112.
[17] Weller, M., Roth, P., Preusser, M., et al. Vaccine-based immunotherapeutic approaches to gliomas and beyond.[J]. Nat Rev Neurol, 2017, 13: 363-374.
[18] Pal, S.K., Agarwal, N., Dizman, N., et al. Vaccine therapy in renal cell carcinoma: attempting to leap over a rising bar.[J] .Lancet Oncol, 2016, 17: 1477-1478.
[19] Che, Y.X.,Yang, Y., Suo, J.G., et al. Induction of systemic immune responses and reversion of immunosuppression in the tumor microenvironment by a therapeutic vaccine for cervical cancer.[J] .Cancer Immunol Immunother, 2020, 69: 2651-2664.
[20] Griffiths, E.A., Srivastava, P., Matsuzaki, J., et al. NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome.[J] .Clin Cancer Res, 2018, 24: 1019-1029.
[21] van de, Loosdrecht Arjan A,van Wetering Sandra,Santegoets Saskia J A M et al. A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia.[J] .Cancer Immunol Immunother, 2018, 67: 1505-1518.
[22] Rosenblatt, J., Avivi, I., Vasir, B., et al. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients.[J] .Clin Cancer Res, 2013, 19: 3640-8.
[23] Rosenblatt, Jacalyn., Stone, Richard, M, Uhl, L., et al. Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. [J] .Sci Transl Med, 2016, 8: 368ra171.
[24] Stroopinsky, D., Liegel, J., Bhasin, M., et al. Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model.[J] . Haematologica, 2021, 106: 1330-1342.
[25] Dombret, H., Gene mutation and AML pathogenesis.[J] .Blood, 2011, 118: 5366-7.
[26] Fujiki, F., Oka, Y., Tsuboi, A., et al. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes. [J] .J Immunother, 2007, 30: 282-93.
[2] Tefferi, A,Vardiman, J.W., Myelodysplastic syndromes. [J] .N Engl J Med, 2009, 361: 1872-85.
[3] Tallman, M.S.,Wang, E.S., Altman, J.K., et al. Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.[J] .J Natl Compr Canc Netw, 2019, 17: 721-749.
[4] Elsayad, K., Oertel, M., Haverkamp, U., et al. The effectiveness of radiotherapy for leukemia cutis.[J] .J Cancer Res Clin Oncol, 2017, 143: 851-859.
[5] Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association,[Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2017)].[J] . Zhonghua Xue Ye Xue Za Zhi, 2017, 38: 177-182.
[6] Chevallier P., Mohty, M., Lioure, B., et al. Allogeneic hematopoietic stem-cell transplantation for myeloid sarcoma: a retrospective study from the SFGM-TC. [J] .J Clin Oncol, 2008, 26: 4940-3.
[7]Creutzig, U.,van den Heuvel-Eibrink Marry M,Gibson, B. et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel.[J] .Blood, 2012, 120: 3187-205.
[8] Saxena, M., van der Burg Sjoerd H, Melief, C. J. M., et al. Therapeutic cancer vaccines.[J] .Nat Rev Cancer, 2021, 21: 360-378.
[9] Arribillaga L., Echeverria, I., Belsue, V., et al. Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens.[J] . J Immunother Cancer, 2020, 8: undefined.
[10] Kim, C.G., Sang, Y.b., Lee, J.H., et al. Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach.[J] .Int J Mol Sci, 2021, 22: undefined.
[11] Cheever, M.A., Higano, C. S., PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.[J] .Clin Cancer Res, 2011, 17: 3520-6.
[12] Rocconi, R.P., Grosen, E.A, Ghamande, S.A., et al. Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.[J] .Lancet Oncol, 2020, 21: 1661-1672.
[13] Kalli, K.R., Block, M.S., Kasi, P. M., et al. Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients.[J] .Clin Cancer Res, 2018, 24: 3014-3025.
[14] Dammeijer, F., Lievense, L.A.,Veerman, G.D., Marijn et al. Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.[J] .J Clin Oncol, 2016, 34: 3204-12.
[15] Ott, P.A., Hu-Lieskovan, S.W.,Chmielowski, B., et al. A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.[J] .Cell, 2020, 183: 347-362.e24.
[16] Sahin, U., Oehm, P., Derhovanessian, E., et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma.[J] .Nature, 2020, 585: 107-112.
[17] Weller, M., Roth, P., Preusser, M., et al. Vaccine-based immunotherapeutic approaches to gliomas and beyond.[J]. Nat Rev Neurol, 2017, 13: 363-374.
[18] Pal, S.K., Agarwal, N., Dizman, N., et al. Vaccine therapy in renal cell carcinoma: attempting to leap over a rising bar.[J] .Lancet Oncol, 2016, 17: 1477-1478.
[19] Che, Y.X.,Yang, Y., Suo, J.G., et al. Induction of systemic immune responses and reversion of immunosuppression in the tumor microenvironment by a therapeutic vaccine for cervical cancer.[J] .Cancer Immunol Immunother, 2020, 69: 2651-2664.
[20] Griffiths, E.A., Srivastava, P., Matsuzaki, J., et al. NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome.[J] .Clin Cancer Res, 2018, 24: 1019-1029.
[21] van de, Loosdrecht Arjan A,van Wetering Sandra,Santegoets Saskia J A M et al. A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia.[J] .Cancer Immunol Immunother, 2018, 67: 1505-1518.
[22] Rosenblatt, J., Avivi, I., Vasir, B., et al. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients.[J] .Clin Cancer Res, 2013, 19: 3640-8.
[23] Rosenblatt, Jacalyn., Stone, Richard, M, Uhl, L., et al. Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. [J] .Sci Transl Med, 2016, 8: 368ra171.
[24] Stroopinsky, D., Liegel, J., Bhasin, M., et al. Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model.[J] . Haematologica, 2021, 106: 1330-1342.
[25] Dombret, H., Gene mutation and AML pathogenesis.[J] .Blood, 2011, 118: 5366-7.
[26] Fujiki, F., Oka, Y., Tsuboi, A., et al. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes. [J] .J Immunother, 2007, 30: 282-93.
Published
2022-03-29
Issue
Section
Original Research Article
Copyright (c) 2022 Shuwei Liu
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear
Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.
